Department of Urology, Maastricht University Medical Centre, Maastricht, the Netherlands.
J Urol. 2013 Dec;190(6):2148-52. doi: 10.1016/j.juro.2013.07.017. Epub 2013 Jul 17.
We evaluated whether patients with overactive bladder and incontinence who discontinued intravesical botulinum toxin therapy can be successfully treated with sacral neuromodulation.
All patients who were referred to our center after discontinuation of botulinum toxin-A between 2005 and 2010 were included in this observational study. All patients underwent test stimulation with sacral neuromodulation and were evaluated with voiding diaries. Success was defined as more than 50% improvement in leakage episodes. Successful test stimulation was subsequently followed by a definitive implant. Patient satisfaction with sacral neuromodulation therapy was evaluated 1 year after the definitive implant.
A total of 20 patients were included in the study. Of these patients 17 (85%) had discontinued botulinum toxin-A because of lack of efficacy and 3 had been treated successfully with botulinum toxin-A but requested a more permanent solution. The mean interval between the botulinum toxin-A and the sacral neuromodulation test stimulation was 23 months. In 14 patients (70%) the test stimulation was successful and they received a definitive implant. Of the 14 patients 5 even showed a decrease of greater than 90% in leakage episodes. One year after implantation 11 patients (79%) were satisfied with the sacral neuromodulation treatment.
Despite the small sample size, this study indicates that patients who are dissatisfied with or in whom botulinum toxin-A treatment fails can respond successfully to sacral neuromodulation. The success rate of the test stimulation was comparable to that of patients who have never been treated with botulinum toxin-A. The 1-year satisfaction rate was comparable that of patients without a history of botulinum toxin-A treatment.
我们评估了患有膀胱过度活动症和尿失禁且已停止膀胱内肉毒杆菌毒素治疗的患者是否可以通过骶神经调节成功治疗。
本观察性研究纳入了 2005 年至 2010 年间因停止使用 A 型肉毒杆菌毒素而转至我们中心的所有患者。所有患者均接受骶神经调节测试刺激,并通过排尿日记进行评估。成功的定义为漏尿发作减少 50%以上。随后对成功的测试刺激进行了确定性植入。在确定性植入后 1 年评估患者对骶神经调节治疗的满意度。
本研究共纳入 20 例患者。其中 17 例(85%)因疗效不佳而停止使用肉毒杆菌毒素-A,3 例曾成功接受肉毒杆菌毒素-A 治疗,但要求更持久的解决方案。肉毒杆菌毒素-A 与骶神经调节测试刺激之间的平均间隔为 23 个月。在 14 例患者(70%)中,测试刺激成功,他们接受了确定性植入。在 14 例患者中,有 5 例漏尿发作减少了 90%以上。植入后 1 年,11 例(79%)患者对骶神经调节治疗满意。
尽管样本量较小,但本研究表明,对肉毒杆菌毒素-A 治疗不满意或无效的患者可以对骶神经调节成功做出反应。测试刺激的成功率与从未接受过肉毒杆菌毒素-A 治疗的患者相似。1 年的满意度与无肉毒杆菌毒素-A 治疗史的患者相似。